Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Analysts

Key Points

• Maze Therapeutics, Inc. has received an average rating of “Buy” from analysts, with five ratings firms issuing buy ratings and an average twelve-month price target of $25.60.
• A significant increase in institutional interest has been noted, with Bank of America boosting its position in Maze Therapeutics by 33.6% in the second quarter.
• The company reported an EPS of (0.77), surpassing the consensus estimate of (0.79), highlighting its financial performance in the recent quarter.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have earned an average rating of "Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.60.

Several equities analysts have recently commented on the stock. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. HC Wainwright initiated coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in shares of Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock valued at $71,000 after purchasing an additional 1,455 shares in the last quarter. CWM LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $28,000. New York State Common Retirement Fund bought a new position in shares of Maze Therapeutics during the 1st quarter valued at about $25,000. Legal & General Group Plc boosted its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $14.05 on Wednesday. The company has a 50-day simple moving average of $14.00 and a 200-day simple moving average of $11.87. Maze Therapeutics has a one year low of $6.71 and a one year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.